Research - FDA confirms that LDL-C remains a viable surrogate endpoint for cholesterol-lowering drugs. ETC-1002 does not need a cardiovascular outcomes study prior to approval, and -1002 should be … Continue Reading
Premium: Read NowResearch - It’s been “risk-off” in equities this week as traders begin to factor in a rate hike from the Fed, and the high-beta biotech sector has … Continue Reading
Read NowResearch - On Affimed's trial delay and Marinus' three-month performance.
Premium: Read NowResearch - Second phase III trial confirms drug profile of plecanatide, allaying any fears that the low diarrhea rate in the first phase III was a fluke. With … Continue Reading
Premium: Read NowResearch - Regeneron’s (REGN) Praluent has been approved by the FDA, and the label essentially meets the Base Case scenario that we wrote about yesterday for Esperion … Continue Reading
Premium: Read NowResearch - Tomorrow is a big day for developmental cholesterol-lowering medications. The FDA will issue an approval decision for Regeneron (REGN) and Sanofi’s (SNY) PCSK9 inhibitor, Praluent (alirocumab).
Read NowResearch - As we theorized early this month, Tekmira Pharmaceuticals (TKMR) is changing its name and re prioritizing drug development efforts around Hepatitis B. Unfortunately, our musings that investors may reward the … Continue Reading
Read Now
